Luminex Corporation (NASDAQ:LMNX) Receives Daily News Impact Score of 0.24
Headlines about Luminex Corporation (NASDAQ:LMNX) have been trending somewhat positive on Sunday, Accern reports. Accern identifies negative and positive press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Luminex Corporation earned a news sentiment score of 0.24 on Accern’s scale. Accern also gave news coverage about the medical instruments supplier an impact score of 47.0024479649907 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the news articles that may have effected Accern’s analysis:
- Luminex Corp. :LMNX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 10, 2017 (finance.yahoo.com)
- Luminex Corporation (NASDAQ:LMNX) Downgraded by TheStreet to C+ (americanbankingnews.com)
- Luminex’s (LMNX) CEO Homi Shamir on Q2 2017 Results – Earnings Call Transcript (seekingalpha.com)
- Edited Transcript of LMNX earnings conference call or presentation 7-Aug-17 8:30pm GMT (finance.yahoo.com)
- Luminex Corporation Reports Second Quarter 2017 Financial Results (finance.yahoo.com)
LMNX has been the subject of a number of research analyst reports. TheStreet raised shares of Luminex Corporation from a “c+” rating to a “b-” rating in a research report on Friday, May 19th. Zacks Investment Research downgraded shares of Luminex Corporation from a “hold” rating to a “sell” rating in a research report on Monday, April 17th. ValuEngine downgraded shares of Luminex Corporation from a “hold” rating to a “sell” rating in a research report on Saturday, July 8th. Jefferies Group LLC increased their target price on shares of Luminex Corporation from $20.00 to $21.00 and gave the stock a “hold” rating in a research report on Tuesday, May 2nd. Finally, BidaskClub downgraded shares of Luminex Corporation from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. Three equities research analysts have rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $21.67.
Shares of Luminex Corporation (LMNX) opened at 19.19 on Friday. The firm has a market cap of $845.72 million, a P/E ratio of 59.41 and a beta of 0.29. The firm has a 50-day moving average of $20.59 and a 200 day moving average of $19.64. Luminex Corporation has a 12 month low of $17.64 and a 12 month high of $23.62.
Luminex Corporation (NASDAQ:LMNX) last posted its earnings results on Monday, August 7th. The medical instruments supplier reported $0.20 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.09 by $0.11. Luminex Corporation had a return on equity of 4.81% and a net margin of 4.72%. The firm had revenue of $76.50 million during the quarter, compared to analyst estimates of $75.45 million. During the same period in the previous year, the company earned $0.33 EPS. The company’s revenue for the quarter was up 19.2% on a year-over-year basis. On average, equities research analysts anticipate that Luminex Corporation will post $0.50 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which was paid on Friday, July 14th. Investors of record on Friday, June 23rd were issued a $0.06 dividend. The ex-dividend date of this dividend was Wednesday, June 21st. This represents a $0.24 annualized dividend and a yield of 1.25%. Luminex Corporation’s dividend payout ratio (DPR) is currently 75.00%.
In related news, Director G Walter Loewenbaum II sold 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 30th. The stock was sold at an average price of $20.07, for a total value of $501,750.00. Following the completion of the sale, the director now directly owns 713,896 shares in the company, valued at approximately $14,327,892.72. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Over the last 90 days, insiders sold 75,000 shares of company stock valued at $1,527,500. Corporate insiders own 6.90% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Luminex Corporation (NASDAQ:LMNX) Receives Daily News Impact Score of 0.24” was first published by Daily Political and is the property of of Daily Political. If you are accessing this article on another domain, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The correct version of this article can be read at https://www.dailypolitical.com/2017/08/13/luminex-corporation-nasdaqlmnx-receives-daily-news-impact-score-of-0-24.html.
Luminex Corporation Company Profile
Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company’s products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments.
Receive News & Ratings for Luminex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex Corporation and related companies with MarketBeat.com's FREE daily email newsletter.